Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Gains from Investment Securities: 2015-2024

Historic Gains from Investment Securities for Kura Oncology (KURA) over the last 10 years, with Dec 2024 value amounting to $703,000.

  • Kura Oncology's Gains from Investment Securities was N/A to $969,417 in Q3 2025 from the same period last year, while for Sep 2025 it was $969,417, marking a year-over-year change of. This contributed to the annual value of $703,000 for FY2024, which is 151.07% up from last year.
  • As of FY2024, Kura Oncology's Gains from Investment Securities stood at $703,000, which was up 151.07% from $280,000 recorded in FY2023.
  • Kura Oncology's Gains from Investment Securities' 5-year high stood at $13.3 million during FY2020, with a 5-year trough of $280,000 in FY2023.
  • Over the past 3 years, Kura Oncology's median Gains from Investment Securities value was $701,000 (recorded in 2022), while the average stood at $561,333.
  • Per our database at Business Quant, Kura Oncology's Gains from Investment Securities soared by 11,308.55% in 2020 and then plummeted by 79.83% in 2022.
  • Over the past 5 years, Kura Oncology's Gains from Investment Securities (Yearly) stood at $13.3 million in 2020, then tumbled by 73.97% to $3.5 million in 2021, then plummeted by 79.83% to $701,000 in 2022, then slumped by 60.06% to $280,000 in 2023, then skyrocketed by 151.07% to $703,000 in 2024.